+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sarcoma Drugs Market by Drug Class, Indication, Route of Administration, End User, Treatment Modality - Global Forecast to 2030- Product Image
Sarcoma Drugs Market by Drug Class, Indication, Route of Administration, End User, Treatment Modality - Global Forecast to 2030- Product Image
Sale

Sarcoma Drugs Market by Drug Class, Indication, Route of Administration, End User, Treatment Modality - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083365
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Sarcoma Drugs Market is undergoing rapid transformation, driven by scientific advances and changing global regulations. Innovations in therapy and evolving access dynamics are reshaping commercial and clinical strategies for stakeholders in oncology.

Market Snapshot: Sarcoma Drugs Market

The Sarcoma Drugs Market grew from USD 1.66 billion in 2024 to USD 1.80 billion in 2025. It is expected to continue growing at a CAGR of 8.14%, reaching USD 2.66 billion by 2030. This expansion reflects the market’s dynamic growth trajectory, propelled by breakthrough targeted treatments, immunotherapy, and an expanding patient base. The landscape features strong investment from biotech and established pharma, while evolving regulatory frameworks and reimbursement models directly impact the pace of innovation and patient access. The primary keyword for this report is "Sarcoma Drugs Market," while secondary keywords include "targeted therapy," "immunotherapy," and "combination therapy."

Scope & Segmentation

  • Drug Class: Antiangiogenic Therapy (PDGF Inhibitors, VEGF Inhibitors), Chemotherapy (Alkylating Agents, Anthracyclines, Antimetabolites, Topoisomerase Inhibitors), Hormonal Therapy, Immunotherapy (Adoptive Cell Therapy, Cancer Vaccines, Checkpoint Inhibitors, Cytokine Therapy), Targeted Therapy (CDK4/6 Inhibitors, MTOR Inhibitors, PARP Inhibitors, Tyrosine Kinase Inhibitors).
  • Indication: Bone Sarcoma (Chondrosarcoma, Ewing Sarcoma, Osteosarcoma), Gastrointestinal Stromal Tumors, Kaposi Sarcoma, Soft Tissue Sarcoma (Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Synovial Sarcoma).
  • Route of Administration: Intramuscular, Intravenous, Oral, Subcutaneous.
  • End User: Ambulatory Surgical Centers, Home Care, Hospitals, Specialty Clinics.
  • Treatment Modality: Combination Therapy (Chemotherapy plus Immunotherapy, Chemotherapy plus Targeted, Immunotherapy plus Targeted), Monotherapy.
  • Regions: Americas (United States – California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies: Novartis AG, Bayer AG, Pfizer Inc., Ipsen S.A., Eisai Co., Ltd., Eli Lilly and Company, Deciphera Pharmaceuticals, LLC, Blueprint Medicines Corporation, Epizyme, Inc., Merck & Co., Inc.

Key Takeaways

  • Adoption of targeted therapy and immunotherapy has redefined clinical pathways, delivering more personalized and durable treatment options for a range of sarcoma subtypes.
  • Strategic collaborations between academic centers, biotech, and large pharma firms are accelerating the development and commercialization of novel oncology agents.
  • Regional disparities in reimbursement and regulatory approval influence access, with tiered pricing and value-based care models gaining traction in key markets.
  • Multi-modal treatment strategies, including combination therapy, are improving response rates and overcoming resistance in challenging clinical scenarios.
  • Investments in companion diagnostics and biomarker-driven selection are optimizing patient outcomes and streamlining clinical trial success.
  • Innovator companies are leveraging manufacturing alliances and geographically diverse pipelines to strengthen supply chain resilience and maintain competitiveness.

Tariff Impact

New US tariffs scheduled for 2025 are set to disrupt global supply chains for pharmaceutical components, increasing manufacturing costs for both innovative and generic sarcoma drug producers. Organizations are investigating onshoring and nearshoring to offset exposure, while smaller biotechs face challenges to remain cost-effective. Proactive stakeholder engagement and flexible tariff exemption strategies are critical to maintain consistent drug access and avoid delays in product delivery. The evolving tariff landscape demands resilient procurement, pricing optimization, and streamlined regulatory navigation.

Methodology & Data Sources

This analysis leverages multi-source research by integrating primary interviews with industry leaders, clinical experts, and payers, as well as secondary research using peer-reviewed journals, regulatory databases, and proprietary clinical trial data. Quantitative models use a bottom-up approach to project product pipelines and market developments while regional insights rely on country-level health technology assessments.

Why This Report Matters

  • It provides decision-makers with actionable insights to navigate clinical innovation, regulatory complexity, and cost-control in the evolving sarcoma landscape.
  • Senior executives can benchmark pipeline and commercialization strategies against emerging trends, segment dynamics, and region-specific opportunities.
  • In-depth segmentation supports resource allocation, investment planning, and technology deployment tailored to distinct patient, provider, and regional needs.

Conclusion

The sarcoma drugs market is being rapidly reshaped by scientific breakthroughs, complex regulations, and shifting global economics. Organizations equipped with granular data and strategic foresight will be well-positioned to maximize market potential and enhance patient outcomes as this landscape evolves.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sarcoma Drugs Market, by Drug Class
8.1. Introduction
8.2. Antiangiogenic Therapy
8.2.1. PDGF Inhibitors
8.2.2. VEGF Inhibitors
8.3. Chemotherapy
8.3.1. Alkylating Agents
8.3.2. Anthracyclines
8.3.3. Antimetabolites
8.3.4. Topoisomerase Inhibitors
8.4. Hormonal Therapy
8.5. Immunotherapy
8.5.1. Adoptive Cell Therapy
8.5.2. Cancer Vaccines
8.5.3. Checkpoint Inhibitors
8.5.4. Cytokine Therapy
8.6. Targeted Therapy
8.6.1. CDK4/6 Inhibitors
8.6.2. MTOR Inhibitors
8.6.3. PARP Inhibitors
8.6.4. Tyrosine Kinase Inhibitors
9. Sarcoma Drugs Market, by Indication
9.1. Introduction
9.2. Bone Sarcoma
9.2.1. Chondrosarcoma
9.2.2. Ewing Sarcoma
9.2.3. Osteosarcoma
9.3. Gastrointestinal Stromal Tumors
9.4. Kaposi Sarcoma
9.5. Soft Tissue Sarcoma
9.5.1. Leiomyosarcoma
9.5.2. Liposarcoma
9.5.3. Rhabdomyosarcoma
9.5.4. Synovial Sarcoma
10. Sarcoma Drugs Market, by Route of Administration
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Oral
10.5. Subcutaneous
11. Sarcoma Drugs Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Home Care
11.4. Hospitals
11.5. Specialty Clinics
12. Sarcoma Drugs Market, by Treatment Modality
12.1. Introduction
12.2. Combination Therapy
12.2.1. Chemotherapy Plus Immunotherapy
12.2.2. Chemotherapy Plus Targeted
12.2.3. Immunotherapy Plus Targeted
12.3. Monotherapy
13. Americas Sarcoma Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Sarcoma Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Sarcoma Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Bayer AG
16.3.3. Pfizer Inc.
16.3.4. Ipsen S.A.
16.3.5. Eisai Co., Ltd.
16.3.6. Eli Lilly and Company
16.3.7. Deciphera Pharmaceuticals, LLC
16.3.8. Blueprint Medicines Corporation
16.3.9. Epizyme, Inc.
16.3.10. Merck & Co., Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. SARCOMA DRUGS MARKET MULTI-CURRENCY
FIGURE 2. SARCOMA DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. SARCOMA DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SARCOMA DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SARCOMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SARCOMA DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 87. CANADA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. CANADA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 89. CANADA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 90. CANADA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 91. CANADA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 92. CANADA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. CANADA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 94. CANADA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 95. CANADA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. CANADA SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. CANADA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 98. CANADA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 99. MEXICO SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 101. MEXICO SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 102. MEXICO SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 103. MEXICO SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 104. MEXICO SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. MEXICO SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 106. MEXICO SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 107. MEXICO SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. MEXICO SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. MEXICO SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 110. MEXICO SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 160. GERMANY SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. GERMANY SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 162. GERMANY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 163. GERMANY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 164. GERMANY SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 165. GERMANY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. GERMANY SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 167. GERMANY SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 168. GERMANY SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. GERMANY SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. GERMANY SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 171. GERMANY SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 172. FRANCE SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 173. FRANCE SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 174. FRANCE SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 175. FRANCE SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 176. FRANCE SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 177. FRANCE SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. FRANCE SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 179. FRANCE SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 180. FRANCE SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. FRANCE SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. FRANCE SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 183. FRANCE SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 196. ITALY SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 197. ITALY SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 198. ITALY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 199. ITALY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 200. ITALY SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 201. ITALY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 202. ITALY SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 203. ITALY SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 204. ITALY SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. ITALY SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. ITALY SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 207. ITALY SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 208. SPAIN SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. SPAIN SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 210. SPAIN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 211. SPAIN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 212. SPAIN SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 213. SPAIN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 214. SPAIN SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 215. SPAIN SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 216. SPAIN SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. SPAIN SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. SPAIN SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 219. SPAIN SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 256. DENMARK SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 257. DENMARK SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 258. DENMARK SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 259. DENMARK SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 260. DENMARK SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 261. DENMARK SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 262. DENMARK SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 263. DENMARK SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 264. DENMARK SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. DENMARK SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. DENMARK SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 267. DENMARK SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 270. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 271. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 272. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 273. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 274. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 275. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 276. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 279. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 280. QATAR SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. QATAR SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 282. QATAR SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 283. QATAR SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 284. QATAR SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 285. QATAR SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 286. QATAR SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 287. QATAR SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 288. QATAR SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. QATAR SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. QATAR SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 291. QATAR SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 292. FINLAND SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 293. FINLAND SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 294. FINLAND SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 295. FINLAND SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 296. FINLAND SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 297. FINLAND SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 298. FINLAND SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 299. FINLAND SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 300. FINLAND SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. FINLAND SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. FINLAND SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 303. FINLAND SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 304. SWEDEN SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 305. SWEDEN SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 306. SWEDEN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 307. SWEDEN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 308. SWEDEN SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 309. SWEDEN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 310. SWEDEN SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 311. SWEDEN SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 312. SWEDEN SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 313. SWEDEN SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 314. SWEDEN SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 315. SWEDEN SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 316. NIGERIA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 317. NIGERIA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 318. NIGERIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 319. NIGERIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 320. NIGERIA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 321. NIGERIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 322. NIGERIA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 323. NIGERIA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 324. NIGERIA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 325. NIGERIA SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 326. NIGERIA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 327. NIGERIA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 328. EGYPT SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 329. EGYPT SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 330. EGYPT SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 331. EGYPT SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 332. EGYPT SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 333. EGYPT SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 334. EGYPT SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 335. EGYPT SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 336. EGYPT SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 337. EGYPT SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 338. EGYPT SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 339. EGYPT SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 340. TURKEY SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 341. TURKEY SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 342. TURKEY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 343. TURKEY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 344. TURKEY SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 345. TURKEY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 346. TURKEY SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2030 (USD MILLION)
TABLE 347. TURKEY SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2030 (USD MILLION)
TABLE 348. TURKEY SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 349. TURKEY SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 350. TURKEY SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 351. TURKEY SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 352. ISRAEL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 353. ISRAEL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2030 (USD MILLION)
TABLE 354. ISRAEL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Sarcoma Drugs market report include:
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.
  • Ipsen S.A.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Deciphera Pharmaceuticals, LLC
  • Blueprint Medicines Corporation
  • Epizyme, Inc.
  • Merck & Co., Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.8 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.66 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Sarcoma Drugs - Global Strategic Business Report - Product Image

Sarcoma Drugs - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Sarcoma Drugs Market Report 2025 - Product Image

Sarcoma Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Undifferentiated Pleomorphic Sarcoma (UPS) - Pipeline Insight, 2025 - Product Image

Undifferentiated Pleomorphic Sarcoma (UPS) - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Kaposi Sarcoma Market by Patient Population, Treatment Modality, Disease Type, Distribution Site, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Kaposi Sarcoma Market by Patient Population, Treatment Modality, Disease Type, Distribution Site, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From

About the Sarcoma Drug Market

Sarcoma is a type of cancer that affects the connective tissues of the body, such as muscle, bone, fat, and blood vessels. Sarcoma drugs are used to treat this type of cancer, and are part of the larger oncology drug market. These drugs are typically used in combination with other treatments, such as surgery, radiation, and chemotherapy. Sarcoma drugs are designed to target the specific type of cancer, and can be used to reduce the size of tumors, slow the growth of cancer cells, and reduce the risk of metastasis. The sarcoma drug market is highly competitive, with many companies developing new treatments and therapies. Some of the major players in the market include Pfizer, Merck, Novartis, Bristol-Myers Squibb, and Eli Lilly. Other companies, such as Amgen, AstraZeneca, and Celgene, are also developing treatments for sarcoma. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.